Bruker Corporation (NASDAQ: BRKR) recently announced the acquisition of Dynamic Biosensors GmbH, or DBS, a pioneering company known for its development in biosensors. The acquisition is aimed at boosting Bruker's biophysical portfolio, which is used for analyzing molecular interactions and kinetics. Financial details of the transaction were not disclosed.
Hence, the latest strategic acquisition is expected to strengthen Bruker's position in the pharma and biotech industries. The acquisition will leverage Bruker's leading high-throughput Surface Plasmon Resonance ("SPR") portfolio and Dynamic Biosensors' unique instruments.
BRKR's Likely Stock Trend Following the News
Subsequent to the news, the share price of BRKR moved north 1% to $67.46 on Wednesday. The company is gaining a high level of synergies from its continuous effort to reinforce its leading position within the pharma and biotech industries. Given the latest acquisition announcement, we expect market sentiment toward BRKR stock to continue to remain positive.
BRKR currently has a market capitalization of $9.97 billion. The company has a trailing four-quarter average earnings surprise of 10.09%.
Significance of Bruker's Latest Acquisition
DBS develops and markets innovative technologies for studying complex molecular interactions and kinetics to support drug discovery in the pharma and biotech industries, as well as in basic and medical research. The new Dynamic Biosensor heliX instrument performs single-cell Interaction Cytometry (scIC) for kinetic measurements directly on cells, retaining the molecules' native membrane environment. Bruker's SPR portfolio includes all new SPR #64 ‘Triceratops', and the 24 ...
